Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Published:2017-11-21 Issue:3 Volume:72 Page:449-459
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Scheel Andreas H¹^ORCID,Baenfer Gudrun²,Baretton Gustavo³,Dietel Manfred⁴,Diezko Rolf²,Henkel Thomas²,Heukamp Lukas C⁵,Jasani Bharat²,Jöhrens Korinna⁴,Kirchner Thomas⁶,Lasitschka Felix⁷^ORCID,Petersen Iver⁸,Reu Simone⁶,Schildhaus Hans-Ulrich⁹,Schirmacher Peter⁷,Schwamborn Kristina¹⁰,Sommer Ulrich³,Stoss Oliver²,Tiemann Markus⁵,Warth Arne⁷,Weichert Wilko¹⁰,Wolf Jürgen¹¹,Büttner Reinhard¹²,Rüschoff Josef²¹²

Affiliation:

1. Institute of Pathology; University Hospital Cologne; Cologne Germany

2. Targos Molecular Pathology GmbH; Kassel Germany

3. Institute of Pathology; University Hospital Dresden; Dresden Germany

4. Institute of Pathology; Charité-University Hospital Berlin; Berlin Germany

5. Institute for Haematopathology Hamburg; Hamburg Germany

6. Institute of Pathology; LMU University Hospital Munich; Munich Germany

7. Institute of Pathology; University Hospital Heidelberg; Heidelberg Germany

8. Institute of Pathology; University Hospital Jena; Jena Germany

9. Institute of Pathology; University Hospital Göttingen; Göttingen Germany

10. Institute of Pathology; TUM University Hospital Munich; Munich Germany

11. Medical Clinic I; University Hospital Cologne; Cologne Germany

12. Institute of Pathology Nordhessen; Kassel Germany

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13375/fullpdf

Reference30 articles.

1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

5. The ‘cancer immunogram’;Blank;Science,2016

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

2. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores;Cancer Treatment and Research Communications;2024

3. Functional Flow Cytometry to Predict PD‐L1 Conformational Changes;Current Protocols;2023-12

4. Artificial intelligence and digital pathology as drivers of precision oncology;Die Onkologie;2023-06-06

5. Potential for companion diagnostic use and inter-rater agreement of programmed death ligand-1 (PD-L1) clone 22C3 expression scores in colorectal cancer;2023-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3